Clinical Trial Update: Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating clemastine fumarate as a remyelinating therapy for acute optic neuritis. The study (ReCOVER) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Optic Neuritis

Drugs mentioned

• Clemastine Fumarate (clemastine fumarate)

Snippet

Sponsor: University of California, San Francisco | Conditions: Optic Neuritis | Phase 2 | Status: RECRUITING